Your browser doesn't support javascript.
Listing of the neutralizing antibodies amubarvimab and romlusevimab in China: Hopes and impediments.
Liu, Miaona; Li, Wei; Lu, Hongzhou.
  • Liu M; National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • Li W; National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
  • Lu H; National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital, Southern University of Science and Technology, Shenzhen, Guangdong, China.
Drug Discov Ther ; 16(4): 196-197, 2022 Sep 17.
Article in English | MEDLINE | ID: covidwho-1994396
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic continues to ravage the world, and the virus' constant evolution has made it increasingly difficult to contain. The combination of the neutralizing antibodies amubarvimab and romlusevimab has recently been introduced as a treatment for COVID-19 in China. Based on its potential to effectively combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its Omicron variant at a modest cost and under medical insurance, this controversial biotherapy is anticipated to be widely available in China. Hopefully, whether and how the proposed medication will alter the treatment of COVID-19 in China will be apparent soon, as well as if it will help to reduce hospitalizations, reduce the incidence of severe illness, or even act as pre-exposure prophylaxis.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Drug Treatment Type of study: Observational study Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Drug Discov Ther Year: 2022 Document Type: Article Affiliation country: Ddt.2022.01055

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Drug Treatment Type of study: Observational study Topics: Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Drug Discov Ther Year: 2022 Document Type: Article Affiliation country: Ddt.2022.01055